JP6193570B2 - 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化 - Google Patents

産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化 Download PDF

Info

Publication number
JP6193570B2
JP6193570B2 JP2012520813A JP2012520813A JP6193570B2 JP 6193570 B2 JP6193570 B2 JP 6193570B2 JP 2012520813 A JP2012520813 A JP 2012520813A JP 2012520813 A JP2012520813 A JP 2012520813A JP 6193570 B2 JP6193570 B2 JP 6193570B2
Authority
JP
Japan
Prior art keywords
antibody
protein
polypeptide
template
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012520813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533307A (ja
JP2012533307A5 (cg-RX-API-DMAC7.html
Inventor
ショート、ジェイ、ミルトン
Original Assignee
バイオアトラ、エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオアトラ、エルエルシー filed Critical バイオアトラ、エルエルシー
Publication of JP2012533307A publication Critical patent/JP2012533307A/ja
Publication of JP2012533307A5 publication Critical patent/JP2012533307A5/ja
Application granted granted Critical
Publication of JP6193570B2 publication Critical patent/JP6193570B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2012520813A 2009-07-17 2010-07-16 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化 Active JP6193570B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27116809P 2009-07-17 2009-07-17
US61/271,168 2009-07-17
PCT/US2010/042302 WO2011009058A2 (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015094521A Division JP6193913B2 (ja) 2009-07-17 2015-05-06 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化

Publications (3)

Publication Number Publication Date
JP2012533307A JP2012533307A (ja) 2012-12-27
JP2012533307A5 JP2012533307A5 (cg-RX-API-DMAC7.html) 2013-08-29
JP6193570B2 true JP6193570B2 (ja) 2017-09-13

Family

ID=43450243

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012520813A Active JP6193570B2 (ja) 2009-07-17 2010-07-16 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化
JP2015094521A Active JP6193913B2 (ja) 2009-07-17 2015-05-06 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化
JP2017109593A Active JP6681131B2 (ja) 2009-07-17 2017-06-02 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015094521A Active JP6193913B2 (ja) 2009-07-17 2015-05-06 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化
JP2017109593A Active JP6681131B2 (ja) 2009-07-17 2017-06-02 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化

Country Status (18)

Country Link
US (6) US8859467B2 (cg-RX-API-DMAC7.html)
EP (6) EP3636759B1 (cg-RX-API-DMAC7.html)
JP (3) JP6193570B2 (cg-RX-API-DMAC7.html)
KR (5) KR101823872B1 (cg-RX-API-DMAC7.html)
CN (2) CN102625848A (cg-RX-API-DMAC7.html)
AU (5) AU2010273974B2 (cg-RX-API-DMAC7.html)
BR (2) BR122015012748A2 (cg-RX-API-DMAC7.html)
CA (2) CA3034484A1 (cg-RX-API-DMAC7.html)
DK (5) DK3042957T3 (cg-RX-API-DMAC7.html)
ES (3) ES2652340T3 (cg-RX-API-DMAC7.html)
HU (1) HUE029328T2 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN00737A (cg-RX-API-DMAC7.html)
MX (3) MX2012000803A (cg-RX-API-DMAC7.html)
MY (2) MY173037A (cg-RX-API-DMAC7.html)
PL (2) PL2907873T3 (cg-RX-API-DMAC7.html)
PT (1) PT3042957T (cg-RX-API-DMAC7.html)
SG (3) SG10201700096VA (cg-RX-API-DMAC7.html)
WO (1) WO2011009058A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017205110A (ja) * 2009-07-17 2017-11-24 バイオアトラ、エルエルシー 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
SG187033A1 (en) 2010-07-16 2013-02-28 Bioatla Llc Novel methods of protein evolution
AU2015242961B2 (en) * 2010-07-16 2017-03-02 Bioatla, Llc Novel methods of protein evolution
JP6121904B2 (ja) 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
WO2013067322A1 (en) * 2011-11-03 2013-05-10 Stc Biologics, Inc. Method for determination of pharmacological properties of recombinant proteins
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
DK3092491T3 (en) * 2014-01-07 2019-02-11 Bioatla Llc Proteins that are targeted orthologs
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
JP7179400B2 (ja) * 2014-05-13 2022-11-29 バイオアトラ インコーポレイテッド 条件的活性型生物学的タンパク質
CA2954066A1 (en) * 2014-07-01 2016-01-07 Stc Biologics, Inc. A method for development of recombinant proteins with fingerprint like similarity to the reference product
KR102615681B1 (ko) 2014-08-28 2023-12-18 바이오아트라, 인코퍼레이티드 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
CA2959786A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
JP7025214B2 (ja) 2015-02-24 2022-02-24 バイオアトラ、エルエルシー 条件的活性型生物学的タンパク質
RU2763916C2 (ru) * 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
CN108473555B (zh) 2015-11-02 2022-10-25 生物蛋白有限公司 条件活性多肽
LT3455261T (lt) 2016-05-13 2022-11-10 Bioatla, Inc. Antikūnai prieš ror2, antikūnų fragmentai, jų imunokonjugatai ir panaudojimas
MX2020000342A (es) 2017-07-11 2020-08-17 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos.
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN113166269B (zh) 2018-11-13 2025-01-07 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
US12478674B2 (en) 2019-04-18 2025-11-25 Bristol-Myers Squibb Company Ipilimumab variants with enhanced specificity for binding at low pH
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN111048154B (zh) * 2019-12-10 2023-06-06 上海药明生物技术有限公司 一种抗体表位作图的方法
CN111462815B (zh) * 2020-03-27 2023-05-02 上海祥耀生物科技有限责任公司 一种抗体库的构建方法及装置
US11506060B1 (en) * 2021-07-15 2022-11-22 Honeywell International Inc. Radial turbine rotor for gas turbine engine
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4522757A2 (en) 2022-05-13 2025-03-19 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
TW202435912A (zh) 2022-08-03 2024-09-16 美商航海家醫療公司 用於穿過血腦屏障之組合物及方法
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957858A (en) 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
WO1989006700A1 (en) 1988-01-21 1989-07-27 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
WO1989009284A1 (en) 1988-03-24 1989-10-05 University Of Iowa Research Foundation Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU5670994A (en) 1992-11-24 1994-06-22 G.D. Searle & Co. Interleukin-3 (il-3) mutant polypeptides
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US8137906B2 (en) 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
CA2438628A1 (en) 2001-02-19 2002-08-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Artificial proteins with reduced immunogenicity
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
WO2002092780A2 (en) * 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
RU2005140664A (ru) * 2003-06-27 2007-08-27 Байорен, Инк. (Us) Просматривающий мутагенез
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
KR20080073293A (ko) * 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
EP2137308B1 (en) * 2007-03-26 2016-08-03 Agenus Inc. Cell surface display, screening and production of proteins of interest
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
EP2217702A4 (en) 2007-11-02 2012-05-16 Scripps Research Inst DIRECTED EVOLUTION USING PROTEINS WITH NON-NATURAL AMINO ACIDS
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
DK3042957T3 (en) 2009-07-17 2018-01-02 Bioatla Llc At the same time, integrated selection and development of human protein performance and expression in production hosts
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017205110A (ja) * 2009-07-17 2017-11-24 バイオアトラ、エルエルシー 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化

Also Published As

Publication number Publication date
US10920216B2 (en) 2021-02-16
JP6681131B2 (ja) 2020-04-15
AU2017203243B2 (en) 2019-07-11
US20210207129A1 (en) 2021-07-08
US10047357B2 (en) 2018-08-14
US20120245036A1 (en) 2012-09-27
ES2581318T3 (es) 2016-09-05
EP2454376A2 (en) 2012-05-23
KR101823872B1 (ko) 2018-01-31
PL3042957T3 (pl) 2018-03-30
KR20180010347A (ko) 2018-01-30
KR20190017070A (ko) 2019-02-19
JP6193913B2 (ja) 2017-09-06
EP3636759B1 (en) 2023-10-11
MX2012000803A (es) 2012-06-01
AU2010273974A1 (en) 2012-02-09
WO2011009058A2 (en) 2011-01-20
IN2012DN00737A (cg-RX-API-DMAC7.html) 2015-06-19
HUE029328T2 (en) 2017-02-28
DK3636759T3 (da) 2023-10-23
EP2454376B1 (en) 2015-12-02
EP2907873A1 (en) 2015-08-19
EP3042957B1 (en) 2017-09-13
AU2015243076A1 (en) 2015-11-05
ES2701931T3 (es) 2019-02-26
JP2012533307A (ja) 2012-12-27
EP3156485B1 (en) 2018-09-12
AU2015243076B2 (en) 2017-02-23
SG10201700096VA (en) 2017-02-27
BR112012001171A2 (pt) 2017-06-13
EP2454376A4 (en) 2013-07-10
PL2907873T3 (pl) 2016-10-31
ES2652340T3 (es) 2018-02-01
US20120165201A1 (en) 2012-06-28
CA2768247A1 (en) 2011-01-20
MY160472A (en) 2017-03-15
AU2010273974A8 (en) 2012-02-23
EP2907873B1 (en) 2016-04-06
JP2017205110A (ja) 2017-11-24
US20240263354A1 (en) 2024-08-08
WO2011009058A3 (en) 2011-04-14
CN102625848A (zh) 2012-08-01
BR112012001171B1 (pt) 2021-09-21
CA3034484A1 (en) 2011-01-20
HK1210623A1 (en) 2016-04-29
JP2015211672A (ja) 2015-11-26
EP3406717B1 (en) 2019-12-11
EP3406717A1 (en) 2018-11-28
EP3042957A1 (en) 2016-07-13
AU2021203220B2 (en) 2023-05-04
SG10201505075TA (en) 2015-07-30
DK3406717T3 (da) 2020-03-16
AU2017203243A1 (en) 2017-06-08
BR122015012748A2 (pt) 2020-01-07
CN107090031A (zh) 2017-08-25
EP3636759A1 (en) 2020-04-15
AU2010273974B2 (en) 2016-01-14
CA2768247C (en) 2019-04-09
KR20120069664A (ko) 2012-06-28
US20150024944A1 (en) 2015-01-22
US8859467B2 (en) 2014-10-14
AU2019203813B2 (en) 2021-03-11
KR20210013294A (ko) 2021-02-03
DK3156485T3 (en) 2019-01-07
AU2021203220A1 (en) 2021-06-10
DK3042957T3 (en) 2018-01-02
AU2019203813A1 (en) 2019-06-20
EP3156485A1 (en) 2017-04-19
US11976381B2 (en) 2024-05-07
KR20220002712A (ko) 2022-01-06
DK2907873T3 (en) 2016-06-13
MX347654B (es) 2017-05-05
SG177687A1 (en) 2012-02-28
US10106788B2 (en) 2018-10-23
US20180371452A1 (en) 2018-12-27
MX392642B (es) 2025-03-19
PT3042957T (pt) 2017-12-21
MY173037A (en) 2019-12-20

Similar Documents

Publication Publication Date Title
JP6193913B2 (ja) 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化
US10829513B2 (en) Methods of protein evolution
HK40026409A (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1236221B (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1236221A1 (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1230231A1 (en) Simultaneous, integrated selection and evolution of human protein performance and expression in production hosts
HK1230231B (en) Simultaneous, integrated selection and evolution of human protein performance and expression in production hosts
HK1210623B (en) Simulataneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160329

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160404

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170810

R150 Certificate of patent or registration of utility model

Ref document number: 6193570

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250